SCHEMBL4719637

SCHEMBL4719637

c1ccc2cc(-c3cc(Nc4cccc5cnccc45)ncn3)ccc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 4/20 0.48
PDE4B Q07343 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK10 P53779 1/20 0.41
SIRT2 Q8IXJ6 2/20 0.40
CCR4 P51679 1/20 0.39
CYP17A1 P05093 1/20 0.39
CYP19A1 P11511 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
KDR P35968 1/20 0.39
ALDH1A1 P00352 6/20 0.39
MAPT P10636 4/20 0.39
KDM4E B2RXH2 3/20 0.39
KMT2A Q03164 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4718692 0.89 TRPV1 (0.49) TRPV1PDE4BCCR4KDRALDH1A1
SCHEMBL4716052 0.89 PDE4B (0.51) TRPV1PDE4BCCR4KDRALDH1A1
SCHEMBL4718504 0.86 TRPV1 (0.59) TRPV1PDE4BCCR4ALDH1A1MAPT
SCHEMBL4716401 0.86 TRPV1 (0.48) TRPV1PDE4BCCR4KDRALDH1A1
SCHEMBL4717088 0.86 MAOA (0.53) TRPV1PDE4BCYP17A1CYP11B1CYP11B2
SCHEMBL4715609 0.85 ACP1 (0.52) TRPV1ALDH1A1MAPTROCK2CYP1A2
SCHEMBL4718686 0.85 ALDH1A1 (0.48) TRPV1PDE4BCCR4KDRALDH1A1
SCHEMBL4715734 0.85 TRPV1 (0.45) TRPV1PDE4BCCR4ALDH1A1MAPT
SCHEMBL4718526 0.84 TRPV1 (0.41) TRPV1PDE4BCCR4KDRALDH1A1
SCHEMBL4717106 0.84 TRPV1 (0.43) TRPV1PDE4BCCR4KDRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 TRPV1 40/4885PDE4B 4041/4885MAPK9 3707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.